CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price surge ... are also using CRISPR technology to address various ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close. CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain ...

In the latest trading session, CRISPR ... The stock outperformed the S&P 500, which registered a daily loss of 5.98%. Meanwhile, the Dow experienced a drop of 5.5%, and the technology-dominated ...

Editas Medicine, Inc.’s EDIT share price has dipped by 5.16%, which has investors questioning if this is right time to buy.

Shares of early-stage biotech stocks, including Biohaven ( BHVN -8.30%), Recursion Pharmaceuticals ( RXRX -3.98%), and CRISPR Therapeutics ( CRSP -1.49%), plunged in March, with the stocks down 35.3%, ...

We are bullish on CRISPR, giving the stock a strong buy rating and a price target of $70 per share ... rights of the CRISPR-Cas9 gene-editing technology. The legal disputes around the patents ...